SXTC China SXT Pharmaceuticals, Inc. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723980 · Fiscal year ends 03/31
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-34.6%
TTM net income YoY-87.8%
TTM EPS YoY97.4%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—
Margins
Gross margin21.9%
Operating margin-625.9%
Net margin-545.2%
FCF margin—
EBITDA margin-619.4%
Returns
ROE-27.5%
ROA-22.0%
ROIC (approx.)—
Asset turnover0.04x
Leverage & solvency
Liabilities / assets14.5%
Debt / equity0.03x
Current ratio7.93x
Interest coverage-113.13x
Cash quality & payout
Operating cash flow / net income0.65x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.14M | $1.74M |
| Cost of revenue | $889,350 | $1.37M |
| Gross profit | $248,702 | $367,427 |
| SG&A expense | $7.13M | $2.76M |
| Operating income | -$7.12M | -$2.68M |
| Interest expense | $62,965 | $648,221 |
| Pretax income | -$6.21M | -$3.30M |
| Net income | -$6.21M | -$3.30M |
| EBITDA | -$7.05M | -$2.60M |
| EPS (basic) | -9.13 | -348.17 |
| EPS (diluted) | -9.13 | -348.17 |
| Weighted avg. shares (diluted) | 679,648 | 9,489 |
| Banking | ||
| Deposits | — | $7.27M |
| Balance sheet | ||
| Cash & equivalents | $28.18M | $18.10M |
| Receivables | $931,567 | $1.30M |
| Inventory | $777,059 | $828,053 |
| Current assets | $34.51M | $21.30M |
| PP&E, net | $117,103 | $178,561 |
| Intangibles | $6,328 | $11,808 |
| Total assets | $34.75M | $21.66M |
| Current liabilities | $4.35M | $6.01M |
| Short-term debt | $355,175 | $8,781 |
| Long-term debt | $644,390 | $96,264 |
| Total debt | $999,565 | $105,045 |
| Total liabilities | $5.05M | $6.22M |
| Shareholders' equity | $29.71M | $15.44M |
| Net debt | -$27.18M | -$17.99M |
| Shares outstanding | — | 91,756 |
| Cash flow statement | ||
| Operating cash flow | -$4.02M | -$2.35M |
| Capital expenditure | — | $2,023 |
| Free cash flow | — | -$2.35M |
| Investing cash flow | -$1.25M | $63,516 |
| Financing cash flow | $14.43M | $8.40M |
| Depreciation & amortization | $73,668 | $82,297 |
| Stock-based compensation | $5.31M | — |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.